Big Win for Secukinumab in Polymyalgia Rheumatic

(MedPage Today) -- LONDON -- The interleukin (IL)-17A inhibitor secukinumab (Cosentyx) was clearly effective in treating polymyalgia rheumatica (PMR) in a phase III trial, researchers reported, even as they also published final data from a failed...
Source
MedPage Today
Opens original article in a new tab



